Accepted Manuscript

Raltegravir blocks the infectivity of red-fluorescent-protein (mCherry)-labeled

HIV-1_{JR-FL} in the setting of post-exposure prophylaxis in NOD/SCID/Jak3^{-/-} mice transplanted with human PBMCs

Hiromi Ogata-Aoki, Nobuyo Higashi-Kuwata, Shin-ichiro Hattori, Hironori Hayashi, Matthew Danish, Manabu Aoki, Chiemi Shiotsu, Yumi Hashiguchi, Akinobu Hamada, Hisataka Kobayashi, Hironobu Ihn, Seiji Okada, Hiroaki Mitsuya

PII: S0166-3542(17)30265-6

DOI: 10.1016/j.antiviral.2017.09.003

Reference: AVR 4143

To appear in: Antiviral Research

Received Date: 9 April 2017

Revised Date: 5 September 2017

Accepted Date: 6 September 2017

Please cite this article as: Ogata-Aoki, H., Higashi-Kuwata, N., Hattori, S.-i., Hayashi, H., Danish, M., Aoki, M., Shiotsu, C., Hashiguchi, Y., Hamada, A., Kobayashi, H., Ihn, H., Okada, S., Mitsuya, H., Raltegravir blocks the infectivity of red-fluorescent-protein (mCherry)-labeled HIV-1_{JR-FL} in the setting

of post-exposure prophylaxis in NOD/SCID/Jak3^{-/-} mice transplanted with human PBMCs, *Antiviral Research* (2017), doi: 10.1016/j.antiviral.2017.09.003.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Raltegravir blocks the infectivity of red-fluorescent-protein (mCherry)-labeled HIV-1_{JR-FL} in the setting of post-exposure prophylaxis in NOD/SCID/Jak3^{-/-} mice transplanted with human PBMCs Hiromi Ogata-Aoki^{a,b}, Nobuyo Higashi-Kuwata^{a,c}, Shin-ichiro Hattori^{c,d}, Hironori Hayashi^{b,c}, Matthew Danish^b, Manabu Aoki^{a,b,e}, Chiemi Shiotsu^f, Yumi Hashiguchi^{g,h}, Akinobu Hamadaⁱ, Hisataka Kobayashi^j, Hironobu Ihn^f, Seiji Okada^d, and Hiroaki Mitsuya^{a,b,c#} ^aDepartments of Hematology and Infectious Diseases, Kumamoto University Graduate School of Biomedical Sciences; ^bExperimental Retrovirology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; ^cExperimantal Retrovirology Section, Department of Refractory Viral Infection, National Center for Global Health and Medicine Research Institute, Tokyo, Japan; ^dDivision of Hematopoiesis, Center for AIDS Research, Kumamoto University, Kumamoto, Japan; ^eDepartment of Medical Technology, Kumamoto Health Science University, Kumamoto, Japan; ^fDepartment of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ^gDepartment of Clinical and Pharmaceutical

Download English Version:

https://daneshyari.com/en/article/8523426

Download Persian Version:

https://daneshyari.com/article/8523426

Daneshyari.com